A pentadecapeptide fragment derived from body protection compound in gastric juice, widely studied for its remarkable tissue repair and anti-inflammatory properties.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a partial sequence derived from a larger protective protein found in human gastric juice, where it was originally identified during the systematic fractionation of gastric secretions in the early 1990s. What distinguishes BPC-157 from many research peptides is the depth of its investigational history, centered almost entirely at a single institution: the University of Zagreb in Croatia, under the direction of Professor Predrag Sikirić and his research team at the Department of Pharmacology.
Sikirić’s group first isolated and characterized the parent gastric protein in the late 1980s, identifying a family of peptide fragments with cytoprotective properties. BPC-157 emerged from this work as the most active and stable fragment. The designation “157” refers to its position within the sequence of the parent compound’s identification process. The peptide has the molecular formula C62H98N16O22 and a molecular weight of approximately 1,419 Da. Unlike many peptides that degrade rapidly in aqueous environments or in the presence of digestive enzymes, BPC-157 demonstrates unusual stability in gastric acid — a property that makes oral administration feasible without enteric coating or specialized delivery systems, distinguishing it from most other research peptides.
Over more than three decades, the University of Zagreb team and collaborating researchers have published an extensive body of work examining BPC-157’s effects across an impressive range of biological systems. Published studies number in the hundreds, covering tendon and ligament healing, gastrointestinal protection, muscle repair, bone healing, neuroprotection, cardiovascular effects, and modulation of the central nervous and endocrine systems. The vast majority of this research uses rodent models — rats and, less commonly, mice — with intriguing consistency of effect across different injury types and tissue targets.
As of 2025, BPC-157 has not received approval from the FDA, EMA, or any other major regulatory agency for any clinical indication. It has not advanced to published Phase II or Phase III human clinical trials, a gap that represents the most significant limitation in the existing evidence base. A Croatian company, PL-10, has been associated with early-stage clinical development, and some Phase I tolerability data exists but has not been published in major peer-reviewed journals. Despite the absence of approved human indications, BPC-157 has attracted substantial interest in the research and sports medicine communities due to its broad range of demonstrated effects in animal models and its apparent safety profile in preclinical toxicology work.
One of the most well-documented molecular mechanisms attributed to BPC-157 is the upregulation of vascular endothelial growth factor (VEGF) and its primary receptor VEGFR2 (KDR/Flk-1) in injured tissues. Adequate vascularization is rate-limiting for tissue repair: without sufficient blood supply, oxygen and nutrient delivery to the wound site is insufficient to sustain the metabolic demands of active tissue regeneration. Research from the Sikirić group and independent investigators has shown that BPC-157 treatment increases VEGF expression in healing tendons, muscle, and mucosal tissue in rat models, accompanied by measurable increases in capillary density at the injury site as assessed by immunohistochemistry.
This pro-angiogenic effect appears to involve early growth response protein 1 (Egr-1), a transcription factor that drives VEGF gene expression and is upregulated by BPC-157 treatment in wound healing models. The cascade — BPC-157 administration → Egr-1 upregulation → VEGF transcription → VEGFR2 signaling → endothelial cell proliferation and migration → new capillary formation — provides a mechanistic framework for the accelerated wound closure and tissue repair observed across BPC-157 animal studies. Additionally, nitric oxide synthase (NOS) activity has been implicated in this angiogenic signaling, as nitric oxide (NO) is a downstream mediator of VEGF-driven endothelial responses. The fact that L-NAME (an NOS inhibitor) partially blunts BPC-157’s healing effects in some animal models provides supporting evidence for the NO component of this pathway.
Tissue repair requires not just cell proliferation but directed cell migration — the movement of fibroblasts, epithelial cells, and other repair-competent cell types toward the site of injury. BPC-157 research has identified the focal adhesion kinase (FAK)-paxillin signaling axis as a key mediator of this migratory response. FAK is a non-receptor tyrosine kinase that localizes to focal adhesions — the molecular anchoring points where cells contact the extracellular matrix — and its phosphorylation status controls the dynamics of cell adhesion, spreading, and migration.
Studies examining tendon fibroblast cultures treated with BPC-157 have shown increased FAK and paxillin phosphorylation, with enhanced in vitro wound scratch closure compared to untreated controls. This suggests BPC-157 actively accelerates fibroblast migration into wound spaces, independent of its effects on proliferation. The FAK pathway also connects to downstream Rho GTPase signaling (Rac1, Cdc42), which reorganizes the actin cytoskeleton to enable the lamellipodia formation required for cell movement. Upstream of FAK, BPC-157’s interaction with growth factor receptors — including the EGF receptor and FGF receptors — has been proposed as an initiating signal, though the specific receptor through which BPC-157 initiates these intracellular signals has not been definitively identified, which represents an important open question in the mechanistic literature.
Nitric oxide plays an extraordinarily diverse set of roles in tissue physiology: it modulates vascular tone, acts as an antimicrobial agent, participates in neural signaling, and regulates inflammatory cell recruitment. BPC-157’s relationship with the NO system is one of the more nuanced aspects of its pharmacology. Research from the Sikirić laboratory has demonstrated that BPC-157 can restore homeostatic NO signaling in situations where it has been pathologically disrupted — either by excessive NO production (as in L-arginine overdose models) or by NO deficiency (as in L-NAME-treated animals).
This bidirectional regulatory effect — sometimes described as a “modulating” rather than simply “activating” or “inhibiting” effect on NOS activity — suggests that BPC-157 does not simply stimulate NO production uniformly, but instead influences the system toward a functional optimum. In the context of gastrointestinal protection, NO from endothelial NOS (eNOS) plays a crucial role in maintaining mucosal blood flow and mucus layer integrity. BPC-157’s ability to restore eNOS-dependent vascular responsiveness in damaged gastric mucosa is thought to underlie part of its cytoprotective effect. In the cardiovascular context, NO-mediated vasodilation may contribute to BPC-157’s observed blood pressure effects in hypertensive rat models, where it has shown the ability to attenuate hypertensive spikes without causing hypotension in normotensive controls — another example of its apparently context-dependent regulatory character.
The tendon and ligament healing data for BPC-157 represents one of the most consistently replicated areas in the compound’s research literature. In a landmark series of experiments, Sikirić and colleagues created standardized Achilles tendon transection injuries in rats and treated animals with BPC-157 via intraperitoneal injection, subcutaneous injection, or oral gavage. Across multiple studies published in journals including the Journal of Orthopaedic Research and Connective Tissue Research, BPC-157-treated animals demonstrated significantly faster functional recovery — as measured by weight-bearing ability and running performance — compared to vehicle-treated controls. Histological analysis revealed more organized collagen fiber alignment, greater cross-sectional area recovery, and reduced inflammatory infiltrate in the BPC-157 groups.
Importantly, the route of administration produced similar outcomes, with oral administration requiring approximately 3 to 5 times the dose used for injection to achieve comparable effects — a finding with practical relevance for research design. Studies have also examined medial collateral ligament (MCL) injuries in rat models, finding that BPC-157 accelerated the transition from the inflammatory phase to the proliferative repair phase of healing. One study using a quadriceps tendon detachment model found that BPC-157-treated animals showed superior reattachment strength at 4 weeks compared to controls, with the improvement correlating with increased VEGF expression and capillary density in the healing tissue. These findings have been partially replicated by independent research groups outside Croatia, adding credibility to the core tendon-healing observations.
Given BPC-157’s origin in gastric juice, it is fitting that its most extensive research base concerns gastrointestinal protection. The Sikirić group has published dozens of studies demonstrating BPC-157’s ability to protect against and reverse gastric ulcers induced by a wide range of agents: ethanol, aspirin and other NSAIDs, indomethacin, corticosteroids, stress, cysteamine, and surgical ligation of gastric vessels. The protective effect in NSAID-induced gastric damage is particularly well-characterized: rats treated with BPC-157 prior to or concurrently with indomethacin showed dramatically reduced ulcer formation, preserved mucosal integrity, and maintained normal gastric mucosal blood flow compared to indomethacin-only controls.
Beyond gastric ulcer protection, BPC-157 has shown therapeutic effects in models of inflammatory bowel disease. In TNBS (trinitrobenzene sulfonic acid)-induced colitis and acetic acid-induced colitis in rats — two of the most widely used experimental IBD models — BPC-157 treatment reduced macroscopic ulcer scores, histological evidence of mucosal damage, and inflammatory cytokine levels in colon tissue. Particularly notable is the finding that oral BPC-157 is effective in these intestinal models, which makes mechanistic sense given its stability in gastric acid: the intact peptide can reach the intestinal mucosa following oral administration, something most peptide drugs cannot achieve. Short-chain bowel syndrome models and anastomotic healing studies have also shown BPC-157 to improve outcomes, with faster wound healing at surgical anastomosis sites and reduced leakage rates in treated animals.
Skeletal muscle crush injury and surgical transection models in rats have been used to examine BPC-157’s myogenic repair effects. Studies published by Sikirić’s group and collaborators in Muscle and Nerve and related journals found that rats treated with BPC-157 following standardized gastrocnemius crush injury showed faster return of grip strength, improved histological repair scores at 7, 14, and 21 days post-injury, and reduced fibrotic tissue formation compared to controls. Satellite cell activation — measured by Pax7 and MyoD expression in the injured muscle — was enhanced in treated animals, suggesting BPC-157 promotes the myogenic precursor response central to skeletal muscle regeneration.
For bone healing, studies using femoral segmental defect models and osteotomy models in rats have demonstrated that BPC-157-treated animals form more callus tissue, achieve radiographic bridging of defects earlier, and show greater bone mineral density at the repair site at 4 and 8 weeks compared to controls. One study specifically examined healing of rat calvaria defects — a particularly challenging model because flat bone repairs through different mechanisms than long bone — and found improved defect fill with organized woven bone in BPC-157-treated animals. Osteocalcin and alkaline phosphatase levels, markers of osteoblast activity, were higher in BPC-157 groups at early time points, consistent with enhanced osteoblastic differentiation and activity. The precise molecular mechanism by which BPC-157 promotes osteogenesis is less well-characterized than its effects on soft tissue, representing an area where further mechanistic research is needed.
BPC-157’s effects on the nervous system represent a substantial and growing portion of its research literature. In traumatic brain injury models using controlled cortical impact or fluid percussion injury in rats, BPC-157 administration (both systemically and intracerebrally in some studies) reduced lesion volume, attenuated cerebral edema, improved neurological deficit scores, and accelerated functional recovery on behavioral tasks including the Morris Water Maze. Neuroprotective effects have also been demonstrated in spinal cord injury models, where BPC-157 treatment after standardized compression injury improved hindlimb motor function and reduced secondary inflammatory damage.
At the neurochemical level, BPC-157 has been shown to modulate dopaminergic and serotonergic neurotransmission. It counteracts the behavioral and neurochemical effects of dopamine receptor antagonists (such as haloperidol) in rodents, suggesting it may interact with dopaminergic signaling at some level, possibly through modulation of receptor expression or downstream signaling rather than direct receptor binding. Similarly, it has been reported to reduce the severity of serotonin syndrome in rat models and to influence the behavioral sequelae of selective serotonin reuptake inhibitor (SSRI) administration. These findings are preliminary and mechanistically puzzling, as they suggest CNS effects beyond what would be expected from a peripherally active peptide — possibly involving vagal afferent signaling from the GI tract to the brain, given BPC-157’s GI origins and activity, or direct CNS penetration through areas of incomplete blood-brain barrier, though this has not been conclusively demonstrated.
The dosing data for BPC-157 comes almost entirely from rodent studies, with the most commonly used experimental doses in the range of 10 to 100 mcg/kg for injection routes. The most frequently cited effective dose in the Sikirić group’s published work is approximately 10 mcg/kg intraperitoneally or subcutaneously in rats, which for a 300g rat corresponds to approximately 3 mcg per animal. Applying standard allometric scaling from rat to human (a factor of approximately 6.2 for body surface area normalization), a human dose equivalent would be approximately 1.6 mcg/kg, or roughly 112 to 130 mcg for a 70 to 80 kg adult — significantly lower than the 200 to 500 mcg doses commonly used in research protocols.
However, dose-response data from the BPC-157 literature shows a relatively flat dose-response curve across one to two orders of magnitude, with effects often maintained at both 10 mcg/kg and 100 mcg/kg in animal studies — suggesting the compound has a broad effective dose range. For oral administration, the effective dose is approximately 3 to 5 times higher than the injectable dose, based on studies where both routes were compared directly in the same injury model. This reflects lower bioavailability of the intact peptide after absorption from the GI tract, even though BPC-157 is stable in the gastric environment. For dosing calculations and unit conversions, the peptide dosing calculator provides a helpful starting reference.
BPC-157 has been studied via intraperitoneal (IP), subcutaneous (SC), intramuscular (IM), oral (gavage), intravenous (IV), topical, and local (intralesional) injection routes in animal models. The most frequently studied routes are IP and SC, both of which produce systemic effects on tissues distant from the injection site — an important observation that suggests systemic rather than purely local mechanisms of action for many of BPC-157’s documented effects.
Oral administration is notable for its practicality and for the fact that it works at all — most peptides of this size would be degraded before reaching systemic circulation. BPC-157’s gastric acid stability allows it to survive stomach transit and reach the intestinal mucosa, where it may exert local GI effects directly and also achieve some degree of systemic absorption, though the fraction absorbed systemically is debated. Topical application has been studied for wound healing and skin applications, with the peptide incorporated into gels or applied directly to wound sites in animal models. Local injection directly into a healing tendon or ligament has been used in some studies to deliver higher local concentrations, though systemic injection produces comparable healing outcomes in many of the same models, suggesting local injection may not be necessary. Intranasal and inhaled routes have not been meaningfully studied for this compound.
The majority of BPC-157 animal studies use once-daily dosing for treatment periods ranging from 7 to 21 days, with some studies extending to 30 days. The healing timeline in the injury models studied — tendon, muscle, bone, GI mucosa — typically spans 2 to 4 weeks in rodents, so once-daily administration throughout this period is the most commonly reported protocol. Some studies use twice-daily dosing, but direct comparisons between once-daily and twice-daily administration have not been a consistent focus of the published literature. For systemic anti-inflammatory or protective effects (such as GI protection against concurrent NSAID use), protective dosing on the same schedule as the injurious agent has been used.
Long-duration studies (beyond 8 weeks) are relatively rare in the BPC-157 literature, meaning the cumulative effects of extended administration are not well-characterized. Research protocols in the community often use 4 to 8 week cycles based on the published healing study timelines, with breaks between cycles, though this cycling approach is precautionary convention rather than a practice established by specific long-term data.
BPC-157 lyophilized powder is reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water) for injection preparations, using the same technique as other research peptides: add BAC water slowly down the inside wall of the vial, allow to dissolve gently without shaking. Because BPC-157 is typically supplied in vials of 5 mg, reconstituting with 2.5 mL of BAC water produces a 2 mg/mL (2,000 mcg/mL) solution, making dosing calculations straightforward. For oral preparations, BPC-157 can be dissolved in sterile water or saline for oral gavage in research settings, though some researchers use enteric-coated capsule preparations for human research application.
Lyophilized BPC-157 is stable for 24 months or longer when stored at -20°C, and maintains stability for extended periods at 4°C if kept dry and protected from light. Reconstituted solution should be refrigerated and used within 28 to 30 days. Notably, BPC-157 appears to retain considerable stability at room temperature compared to more fragile peptides — consistent with its characterization as an unusually stable compound — but cold storage remains the standard best practice. The AI research coach can help with specific preparation and handling questions.
Toxicology data for BPC-157 is more extensive than for many research peptides, given the length and breadth of the Sikirić group’s published work. Acute and subchronic toxicity studies in rats and mice have consistently found no observable adverse effects at doses several orders of magnitude above the effective therapeutic dose. The Sikirić group has reported that doses up to 100-fold higher than the effective dose in healing studies produced no signs of toxicity, organ damage (assessed histologically), or behavioral abnormality. No formal LD50 determination has been published in the peer-reviewed literature, as doses high enough to achieve lethality were not reached in rodent toxicology work at practical injection volumes.
Reproductive toxicity and long-term carcinogenicity studies have not been reported in the published literature, which is a meaningful evidence gap. The compound’s apparent lack of receptor selectivity — it seems to affect multiple organ systems through multiple mechanisms — makes formal organ-specific toxicology assessment challenging. Chronic administration studies (beyond 30 days) are limited in number, and none have been specifically designed as formal toxicology studies with histopathological endpoints across all major organ systems.
In the animal literature, BPC-157 has not been associated with the blood pressure elevation, edema, or glucose metabolism disruption seen with some other research peptides. Its NO system effects suggest it may influence vascular tone, but the observed effect in animal studies has been normalization of dysregulated vascular function rather than unidirectional pressure changes. No documented drug interactions have been identified in the published literature, though the compound’s activity across multiple receptor systems and signaling pathways makes formal drug interaction assessment important for any future clinical development.
BPC-157’s modulatory effects on dopaminergic and serotonergic systems raise theoretical considerations about concurrent use with psychoactive medications — SSRIs, antipsychotics, dopaminergic medications — though no specific interactions have been documented in research to date. The absence of published human clinical trial data means that human-specific considerations around injection-site reactions, systemic tolerability, and idiosyncratic responses have not been formally characterized.
The BPC-157 literature has significant structural limitations that must be acknowledged. First, the overwhelming majority of published work originates from a single research group at the University of Zagreb. While the quality of their methodology is generally sound, independent replication by other labs is limited relative to the volume of published studies. Second, no published Phase II or III human clinical trials exist as of 2025, meaning all of the organ-level and systemic effects described in this article are derived from rodent research. The translational gap from rat to human is particularly relevant here given the diversity of biological systems studied. Third, the proposed mechanisms for BPC-157’s broad effects — spanning GI protection, tendon healing, neural repair, and cardiovascular function — are not fully integrated into a unified molecular theory, suggesting either multiple independent mechanisms or a fundamental signaling interaction that has not yet been fully characterized. Despite these limitations, BPC-157 remains one of the most extensively studied synthetic peptides in the preclinical literature. This content is for research and informational purposes only and does not constitute medical advice.
The name reflects its origin: BPC-157 is derived from a naturally occurring protein found in human gastric juice that was identified for its protective properties against gastric mucosal damage. The “body protection” designation was given by Sikirić’s team to describe the broader cytoprotective character of the compound as their research expanded from the stomach to other organ systems. The numbering (157) reflects its position in the experimental screening series that identified it as the most active fragment of the parent protein. The name has since taken on a broader connotation as evidence accumulated demonstrating protective and restorative effects across multiple organ systems — a kind of systemic tissue guardian role — though researchers are careful to note this characterization needs further human clinical validation.
Unlike most peptides of comparable size, BPC-157 can survive oral administration because of its remarkable stability in gastric acid. Studies from the Sikirić group have directly compared oral and injectable administration in the same injury models and found that oral administration produces comparable healing outcomes, though at approximately 3 to 5 times the dose required for injection. This dose multiplier likely reflects lower systemic bioavailability via the oral route, even though the peptide survives gastric transit. For localized GI conditions — gastric ulcers, intestinal inflammation, mucosal healing — oral administration may actually be more advantageous than injection because it delivers the peptide directly to the affected tissue. For systemic conditions involving tendons, muscle, or bone, both routes appear effective in animal studies. The dosing calculator can help with oral-to-injectable dose conversions.
The timeline varies considerably by tissue type and injury model. In gastrointestinal models, protective effects against acute ulcer formation are observed within 24 hours of administration, and established ulcers show measurable improvement within 48 to 72 hours in rat studies. For tendon healing, functional improvements (weight-bearing, running capacity) typically emerge within 7 to 14 days of daily treatment, with histological improvements in collagen organization visible by day 14 to 21. Bone healing studies observe accelerated callus formation and increased bone density at 4 to 8 weeks. Neurological recovery in CNS injury models shows improvements within 7 to 14 days on behavioral assessments. These timelines are from rodent models and would be expected to scale longer in larger mammals including humans, given the slower metabolic rate and tissue repair kinetics at human scale.
BPC-157 does not appear to directly stimulate or suppress major endocrine axes — it does not affect GH, LH, FSH, testosterone, or cortisol levels in the published animal literature in ways that would suggest endocrine disruption. Unlike peptides such as CJC-1295 or ipamorelin, BPC-157 is not designed to interact with the pituitary or hypothalamic-gonadal axis. Some indirect hormonal effects have been described — for example, modulation of stress-axis responsiveness in some behavioral studies — but these appear to be secondary consequences of the compound’s systemic protective and anti-inflammatory effects rather than primary endocrine actions. This relative hormonal neutrality is considered one of BPC-157’s practical advantages in research design, as it can be studied alongside other compounds without complicating the endocrine picture.
BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) both promote tissue repair but through distinct mechanisms. TB-500 primarily acts through actin sequestration and the promotion of angiogenesis and cell migration via thymosin beta-4’s interaction with G-actin, reducing polymerized actin available for cytoskeletal rigidity and thereby facilitating cell migration. BPC-157 operates through VEGF upregulation, FAK-paxillin signaling, and NO modulation. TB-500 has a broader documented anti-inflammatory effect in some models, while BPC-157 has a more extensive literature covering GI protection — an area where TB-500 has minimal data. Some researchers study both compounds in combination, theorizing complementary mechanisms. Both remain preclinical research compounds without human clinical approval. Browse the peptide database for direct comparison entries on both compounds.
BPC-157 is notably more stable than many research peptides at ambient temperatures, consistent with its documented resistance to gastric acid and proteolytic enzymes. Brief exposure to room temperature — such as during shipping or handling — is unlikely to substantially degrade lyophilized BPC-157. Reconstituted solution is less stable than the dry powder and should be returned to refrigeration promptly, but short exposure to room temperature (a few hours) during preparation and injection should not significantly compromise potency. Long-term storage at room temperature is not recommended. Direct sunlight and heat (above 30°C) accelerate degradation of both lyophilized and reconstituted forms. For optimal shelf life: store lyophilized powder at 4°C or -20°C, store reconstituted solution at 4°C, and protect from light at all stages.
The published clinical evidence for BPC-157 in humans is extremely limited. A small number of safety/tolerability assessments have been conducted under the auspices of PL-10, a Croatian biotech company associated with commercializing the compound, but these have not been published in major peer-reviewed journals as of 2025, and no Phase II or III trial results are in the public literature. The compound’s extensive preclinical record stands in notable contrast to the near-absence of human clinical data — a situation that reflects both the difficulty and expense of formal drug development and the fact that BPC-157 has remained primarily in the academic research domain. This absence of human clinical data is the most important caveat to any discussion of BPC-157’s potential benefits in humans. Consult the AI research coach for the most current information on trial status.
These two compounds have completely different mechanisms of action and target systems — BPC-157 primarily affects local tissue repair, GI protection, and NO/VEGF signaling, while CJC-1295 acts on the hypothalamic-pituitary axis to stimulate GH and IGF-1 production. There is no documented antagonism between them in the published literature, and their distinct mechanisms theoretically allow concurrent research use without direct pharmacological interference. Some research protocols combine a systemic anabolic compound (like a GHRH analog) with a tissue-directed repair compound (like BPC-157) for musculoskeletal recovery applications. However, no published animal or human studies have specifically examined the combination, meaning any synergistic or additive effects are speculative. Each compound should be evaluated on its own merits based on the specific research context.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.